




This strategic partnership is poised to make significant contributions to neurodegenerative disease research, fostering innovation and accelerating the development of new treatments that can potentially change lives.

A unique Preclinical and regulatory package



Key Objectives of the Partnership:

- Enhanced Regulatory Environment:** Leverage Cynbiose's advanced QMS environment to provide regulatory-ready preclinical studies, offering critical insights for advancing novel treatments.
- Accelerated Drug Development:** Utilise Motac's innovative research methodologies to identify and validate new therapeutic targets, accelerating the pathway from discovery to clinical trials.
- Collaborative Research Programs:** Launch joint research initiatives that combine both organisations' scientific expertise and technological capabilities to address the most pressing challenges in central nervous system disease research.
- Global Impact:** Strengthen the global research community's efforts to combat central nervous system disease by sharing findings and advancements through collaborative publications and presentations at international scientific conferences.
- Focus on animal welfare and ethics:** Thanks to its worldwide footprint, the partnership has access to brand-new animal facilities in both France and China, enforcing the highest industry standards of animal welfare in all their research sites.

About Cynbiose

Cynbiose is a premier preclinical CRO specialised in the use of non-human primate models for the study of human diseases. With focuses on translational research, Cynbiose provides comprehensive services that include model development, pharmacology studies, and regulatory support to advance drug discovery and development. For more information, visit www.cynbiose.com.

About Motac Neuroscience

Motac Neuroscience is a leading research organisation dedicated to understanding and treating neurodegenerative diseases. Through innovative research and drug development, Motac Neuroscience aims to bring effective therapies to patients suffering from conditions such as Parkinson's and Alzheimer's disease. For more information, visit www.motacneuroscience.com.

Media Contact:

For Cynbiose:

Erwan Corcuff

CBO

erwan.corcuff@cynbiose.com

+33 6 08 41 21 86

For Motac Neuroscience:

Leslie Largeais

Community Manager

leslie.largeais@motac.com

+33 5 33 51 48 63